Loading...
XSHE002286
Market cap358mUSD
Jan 10, Last price  
7.11CNY
1D
-3.00%
1Q
0.85%
Jan 2017
-57.65%
IPO
-20.20%
Name

Baolingbao Biology Co Ltd

Chart & Performance

D1W1MN
XSHE:002286 chart
P/E
48.71
P/S
1.04
EPS
0.15
Div Yield, %
1.89%
Shrs. gr., 5y
0.10%
Rev. gr., 5y
7.85%
Revenues
2.52b
-6.96%
257,342,744414,325,569536,554,950525,399,637720,615,475950,773,441978,027,983900,769,114910,710,3221,196,281,6961,377,424,2591,592,996,1891,730,012,4581,805,170,0752,054,578,2682,764,976,9722,712,745,3172,523,914,007
Net income
54m
-59.47%
20,007,53033,296,28744,777,23439,273,83642,804,52555,721,63567,325,73841,931,12823,922,42640,945,99349,342,74349,621,88742,952,99535,233,72249,861,881201,579,400133,168,83953,969,019
CFO
282m
+815.86%
19,121,86178,975,088110,771,42644,510,31027,448,383171,698,98394,152,65285,597,750101,769,16977,485,824108,983,6130133,050,032153,953,675398,458,455206,267,70230,821,782282,283,397
Dividend
Mar 08, 20240.08 CNY/sh
Earnings
Feb 27, 2025

Profile

Baolingbao Biology Co.,Ltd. manufactures corn-based health and food ingredients in China and internationally. The company offers isomalto-oligosaccharide, galacto-oligosaccharides, fructose-oligosaccharides, and erythritol products; high fructose corn syrups, crystalline fructose products, sugar alcohols, and resistant dextrin-soluble corn fiber and polydextrose products; starch sugars, such as trehalose, maltodextrin, and glucose syrup products; terminal products; and corn steep liquors, corn husk sprayed products, and corn gluten meal products. Its products are used in various food items, such as beverages, dairy, bakery, candy, meat, honey, seafood, canned food, condiment, health food, infant nutrition, fermentation, and animal nutrition, as well as in various fields, including daily chemicals, pharmaceuticals, cosmetics, etc. The company was founded in 1997 and is based in Yucheng, China.
URL
https://www.blb-cn.com/
IPO date
Aug 11, 2009
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,523,914
-6.96%
2,712,745
-1.89%
Cost of revenue
2,448,404
2,471,900
Unusual Expense (Income)
NOPBT
75,510
240,845
NOPBT Margin
2.99%
8.88%
Operating Taxes
11,146
23,521
Tax Rate
14.76%
9.77%
NOPAT
64,365
217,324
Net income
53,969
-59.47%
133,169
-33.94%
Dividends
(49,758)
(22,309)
Dividend yield
1.70%
0.66%
Proceeds from repurchase of equity
(7,275)
(1)
BB yield
0.25%
0.00%
Debt
Debt current
213,193
335,139
Long-term debt
38,390
173,739
Deferred revenue
60,073
Other long-term liabilities
59,933
10,792
Net debt
(277,313)
(196,600)
Cash flow
Cash from operating activities
282,283
30,822
CAPEX
(152,231)
Cash from investing activities
(148,095)
Cash from financing activities
(270,142)
63,141
FCF
172,009
(224,115)
Balance
Cash
242,736
375,949
Long term investments
286,161
329,529
Excess cash
402,701
569,841
Stockholders' equity
1,018,973
1,185,835
Invested Capital
1,892,056
2,000,742
ROIC
3.31%
12.25%
ROCE
3.29%
9.37%
EV
Common stock shares outstanding
359,793
369,913
Price
8.12
-10.67%
9.09
-32.77%
Market cap
2,921,523
-13.11%
3,362,513
-32.65%
EV
2,644,210
3,165,913
EBITDA
206,273
346,470
EV/EBITDA
12.82
9.14
Interest
24,239
26,539
Interest/NOPBT
32.10%
11.02%